AusBiotech is calling for expressions of interest from researchers and inventors interested in pitching their innovations at our upcoming Early Stage Innovation Forum (ESIF), which will be held at the AusBiotech 2024 national conference in Melbourne.
The ESIF rapid-fire pitch competition allows presenters to pitch their early-stage innovation to a panel of expert judges for feedback. The October 30 competition focuses on early-stage human therapeutic and enabling technology projects.
This exclusive opportunity offers early-stage projects and technologies the chance to gather feedback essential for commercialising them from a panel of industry experts, corporate VCs, and early-stage investors.
During a seven-minute presentation, presenters will be required to outline the problem they are trying to address, their innovative approach to solving the problem, the technology’s competitive advantage, development plan and investment proposal. Submissions are open to investible projects from Australian research institutions or companies seeking seed or series A investment.
Companies that have advanced past seed and series A investment are encouraged to submit their expression of interest to present at Australia’s premier life science investment conference, AusBioInvest, in Melbourne on October 29.
The Forum is run bi-annually and, together, features presentations from Australia's local research institutes, universities, hospitals, and pre-series A companies, in the areas of human therapeutics, enabling technologies, medical devices, diagnostics, and digital health.
QIMR Berghofer’s Associate Professor Michelle Wykes, joint winner of Best Translational Research at the AusBiotech 2023 ESIF, said, “I am so grateful for the opportunity to present my work as a medical researcher and founder to leading industry experts, VCs and investors at the Early-Stage Innovation Forum. My company Fovero Therapeutics [was] just six months old, and the event marked my first time making a public pitch to the investment community. I was incredibly excited to win and the experience has given me a huge shot of confidence as I continue promoting Fovero’s work to investors.
“At the end of the day, events like the ESIF keep spurring me forward in my ultimate goal - to improve outcomes for cancer patients who desperately need more treatment options.”
Read about the AusBiotech 2023 ESIF winners, Associate Professor Michelle Wykes (QIMR Berghofer) and Dr Craig McIntosh (Murdoch University), in the April 2024 edition of the Australasian Biotechnology journal here (pages 16-18).
To register your project or company to present at the ESIF, visit the AusBiotech 2024 website.
Submissions received by 1 September will be reviewed by the appointed Advisory Group, and applicants will be contacted with further information once the evaluation process is complete on or before 11 September 2023.